Chart analyst John Kosar explains how to trade two stocks, he believes, are at key inflection points.» Read More
What does the future of healthcare look like? CNBC's Meg Tirrell reports live in Philadelphia at the Klick Ideas exchange with a closer look.
CNBC's Meg Tirrell reports on the latest Alzheimer's data.
This biotech start-up is using 3-D bio-printing and living human cells for nipple reconstruction surgery for breast cancer survivors who had mastectomies.
CNBC's Meg Tirrell reports the latest action happening in the cholesterol drug pipeline.
Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?
Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.
Regeneron CEO Leonard Schleifer talks about an FDA panel's approval of Sanofi-Regeneron's new cholesterol-lowering drugs.
CNBC's Dominic Chu reports summer is on the way but there are a couple of sectors that have gone cold.
Abrar Mir, managing partner at Quadria Capital Fund, says the $300 million raised for healthcare investments in Asia is "a drop in the ocean" compared to the region's growth rate.
CNBC's Meg Tirrell reports on a FDA panel considering whether to approve the first in a new class of drugs many experts believe could cut the risk of heart attacks and strokes.
Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.
Reports of a $18-billion bid by Shire for Swiss biotech firm Actelion suggest that the European pharma deal-making flurry is far from over.
CNBC's Meg Tirrell reports on the woman's libido drug.
A drug to treat low female sexual desire should be approved with strict measures to ensure patients are aware of its risks, an FDA panel concluded.
The U.S. Securities and Exchange Commission filed a lawsuit over an alleged fake offer to buy Avon Products.
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
CNBC's Meg Tirrell speaks with Dr. Richard Pazdur, FDA Cancer Czar, about immunotherapy and drug innovation at the American Society of Clinical Oncology Conference.
Patrick Mahaffy, Clovis Oncology CEO, weighs in on drug prices, business development, and immunotherapy with CNBC's Meg Tirrell.
Michael Yee, RBC Capital Markets biotech analyst, gives perspective to Puma Biotech and other action in the pharmaceutical industry.
Get the best of CNBC in your inbox